Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice-Reference-Cited by-同舟云学术

Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice

Published:2018-05 Issue:5 Volume:11 Page:
ISSN:1941-7640
Container-title:Circulation: Cardiovascular Interventions
language:en
Short-container-title:Circ Cardiovasc Interv

Author:

Zanchin Thomas¹,Temperli Fabrice¹,Karagiannis Alexios²,Zanchin Christian¹,Räsänen Markus¹,Koskinas Konstantinos C.¹,Stortecky Stefan¹,Hunziker Lukas¹,Praz Fabien¹,Blöchlinger Stefan¹,Moro Christina¹,Moschovitis Aris¹,Seiler Christian¹,Billinger Michael¹,Heg Dik¹,Pilgrim Thomas¹,Valgimigli Marco¹,Windecker Stephan¹,Räber Lorenz¹

Affiliation:

1. From the Department of Cardiology, Bern University Hospital, Switzerland (T.Z., F.T., C.Z., M.R., K.C.K., S.S., L.H., F.P., S.B., C.M., A.M., C.S., M.B., D.H., T.P., M.V., S.W., L.R.)

2. CTU Bern, and Institute of Social and Preventive Medicine, University of Bern, Switzerland (A.K.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference32 articles.

1. Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease

2. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

3. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).;Valgimigli M;Eur Heart J,2018

4. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.;Cannon CP;J Am Coll Cardiol,2007

5. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry – Informing optimal antiplatelet strategies;Clinical and Translational Science;2024-08

2. Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial;European Heart Journal - Cardiovascular Pharmacotherapy;2024-07-18

3. Incidence and pattern of urgent revascularization in acute coronary syndromes treated with ticagrelor or prasugrel;Clinical Research in Cardiology;2024-05-13

4. Nonadherence to ticagrelor versus clopidogrel and clinical outcomes in patients with ACS. Results from the CREA-ARIAM registry;Revista Española de Cardiología (English Edition);2024-02

5. Falta de adherencia a ticagrelor frente a clopidogrel y riesgo de eventos en pacientes con SCA. Resultados del registro CREA-ARIAM;Revista Española de Cardiología;2024-02